Floatz logo

Trastuzumab Deruxtecan

Estrogen-Receptor Positive Breast Cancer

Danish Breast Cancer Cooperative Groupantibody_drug_conjugatePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

76 Active assets in the Estrogen-Receptor Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Palbociclib
Forward Pharmaceuticals Co., Ltd.
Phase 3BB
Capivasertib
Imperial College London
Phase 2BB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →